

Docket No. 10806-64

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on October 14, 1998

Lauren E. Mains
Lauren E. Mains



PATENT

64 1641 # 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Vincente Días et al : Paper No.: ____
Serial No.: 09/158,272 : Group Art Unit: 1641
Filed: September 22, 1998 : Examiner:

For: **Use of Beta Recombinase in Eukaryotic Cells, Especially for Transgenic Work**

TRANSMITTAL OF CERTIFIED PRIORITY DOCUMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The present application claims priority under 35 U.S.C. §119 of Swedish Application No. 9703663-6 filed October 8, 1997. A certified copy of the priority application is submitted herewith. As the priority application is in the English language, all of the requirements of 35 U.S.C. §119 have been met.

Respectfully submitted,

By Holly D. Kozlowski
Holly D. Kozlowski, Reg. No. 30,468
Attorney for Applicants
DINSMORE & SHOHL LLP
1900 Chemed Center
255 E. Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

371945.01

RECEIVED
TTFM CENTER
OCT 21 AM 8:24

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) Sökande *Pharmacia & Upjohn AB, Stockholm SE*
Applicant (s) *Consejo Superior de Investigaciones, Madrid ES*

(21) Patentansökningsnummer *9703663-6*
Patent application number

(86) Ingivningsdatum *1997-10-08*
Date of filing

Stockholm, 1998-09-17

*För Patent- och registreringsverket
For the Patent- and Registration Office*

Åsa Dahlberg

Åsa Dahlberg

Avgift
Fee *170:-*

RECEIVED
OCT 21 1998
59 OCT 21 AM 8:24

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

beta recombinase

5 The present invention relates to the use of prokaryotic recombinase in eukaryotic cells, especially for transgenic work in eukaryotic cells.

It also relates to the use of prokaryotic beta recombinase for intramolecular recombination in eukaryotic cells and for mediating exclusively intramolecular reactions.

10 The use of the gene coding for beta recombinase for catalysing site-specific resolution (deletion) of DNA sequences when the two target sequences (DNA sequences containing *six* sites) in a plasmid (extrachromosomal target) introduced in the cell by transfection or when the target sequences are integrated in the genome as chromatin associated structures, at several locations is also disclosed.

15

INTRODUCTION

Several methods have been developed allowing the manipulation of
20 mammalian genomes in order to elucidate the relevance and function of particular genes of interest. Among them, the development of transgenic mouse strains and gene targeting technologies have turned out to be particularly useful (1, 2). These techniques have undergone a new advance with the characterization and application of site-specific recombinases (3).

25 Site-specific recombinases can be clustered into two major families. The first one (the Int family) comprises those enzymes that catalyse recombination between sites located either in the same DNA molecule (intramolecular recombination leading to resolution or inversion) or in separate DNA molecules (intermolecular recombination leading to integration) (4-7). The later property has been exploited to
30 allow targeted insertion of specific sequences in precise locations (8, 9). The recombinases used for manipulating mammalian genomes are mainly the Cre and the Flp proteins, which belong to the Int family (3). The target sequences for these

enzymes, named *loxP* sites for the Cre enzyme and FRT for Flp, consist on a short inverted repeat to which the protein binds. The recombination process is operative through long distances (up to 70 kb) in the genome. Using these enzymes, several authors have reported site- and tissue-specific DNA recombination in murine models (10-13), chromosomal translocations in plants and animals (14-16) and targeted induction of specific genes (17). For instance, expression of Cre from the *lck* proximal promoter leads to specific recombination in thymus (10). The gene encoding DNA polymerase beta has been tissue-specifically deleted using the same strategy (11). In a different approach, the SV40 large tumor antigen has been specifically activated in the lenses of mice, resulting in tumours at that location and not in the rest of the animal (18). The Cre-*loxP* strategy has also been used in combination with inducible promoters, like the case of the interferon gamma inducible promoter, that was used to provoke gene ablation in liver with high efficiency and with less extent in other tissues (12). This powerful site-specific recombination system, however, only allow the induction of a reduced number of recombination event in the same genome. Since each recombination reaction leaves a target sequence for the recombinase in the genome at the crossover site, and because integrases (e.g. Cre and Flp) can catalyze intermolecular recombination, the whole process may lead to undesired chromosomal rearrangements. This general limitation has been proposed to be partially solved by the use of mutant versions of the *loxP* sequences (18).

The second family of recombinases includes those enzymes that catalyse recombination only when the sites are located in the same DNA molecule (resolution and / or inversion); they are collectively termed resolvases/invertases (19). These site-specific recombinases, which are constrained to intramolecular reactions, could have an advantage over the Int family of recombinases. beta recombinase, which belongs to the resolvases/invertases family, catalyses exclusively intramolecular deletions and inversions of DNA sequences located between two target sites for the recombinase, termed *six* (20-22). Each *six* site comprises 90 bp and is composed by two binding sites for the recombinase, termed I and II (20, 21, see Fig. 1). beta recombinase is encoded by the beta gene of the Gram-positive-broad-host-range plasmid pSM19035 (22-25).

The earlier known Cre system appears to be limited in the sense that it allows the induction of a reduced number of recombination events within the same mouse genome. When a conditional knockout mouse is made using this system, a *loxP* site remains in the genome and constitutes a potential target for another recombination event of unknown consequences. This problem would be fully overcome using an exclusively intramolecular site-specific recombinase.

Figures:

Figure 1: A and B. Schematic representation of the site specific recombination mechanism mediated by IRAP and the plasmids used.

Figure 2. A - F. IRAP Expression

Figure 3. Functional expression of IRAP

Figure 4. IRAP-mediated site specific recombination.

15

THE INVENTION

The scope of the invention is defined by the attached claims.

In the example the use of the prokaryotic site-specific beta recombinase for the manipulation of mammalian genomes is explored. The cloning and expression in eukaryotic cells of the gene coding for beta recombinase is described and its ability to catalyse site-specific resolution (deletion) of DNA sequences when the target sequences are either in a plasmid (extrachromosomal target) introduced in the cell by transfection, or integrated in the genome as chromatin associated structures, at several locations is shown. This activity is termed IRAP, for intramolecular recombination activity mediated by the beta protein. By target sequences is meant *six* site or DNA sequences containing the natural *six* sites or modified versions that allow recombination activity

Our results show that beta recombinase is active in an eukaryotic environment, using the machinery/factors provided by the host cell and that beta recombinase can accurately and efficiently catalyse site-specific recombination in mammalian genomes.

We show that the prokaryotic beta recombinase can be functionally expressed in eukaryotic cells and can promote the deletion of DNA sequences located between directly oriented target sites (intramolecular recombination activity mediated by the beta protein) in mammalian cells, IRAP. The availability of a tool like IRAP system, that can only catalyse intramolecular site-specific recombination, creates a wide variety of possibilities for the programmed modification of eukaryotic genomes, especially if combined with already-existing methods. For instance, a gene of interest could be engineered in order to have an exon or a group of exons flanked with *loxP* /FRT and *six* sites. This would allow the study of gene product influence in two distinct tissues or in the same tissue in different developmental stages, through differential control of Cre/Flp and IRAP expression. Alternatively, two related genes could be inactivated at the same time or at two related stages. The use of inducible promoters would also allow more specific spatio-temporal control of the recombination event.

15

The possible applications and advantages of this new system is further elaborated under DISCUSSION and CONCLUSION

20 Example 1.

MATERIALS AND METHODS

Plasmids and cloning

25 Plasmids pBT233 (23), pBT338 and pCB8 (20) and pLXSN, which carries the resistance marker for G418 (26), have been previously described. The eukaryotic expression vector pSV2 beta globin (27) was kindly provided by Dr. J. Ortin (CNB). The expression plasmid pSV beta was constructed by PCR amplification of the coding sequence for the IRAP from the plasmid pBT233 . The primers used for PCR were:

30 betaUP 5'-GAGAGAAAGCTTGGTTGGTTGAAAATGGCT-3'
betaDO 5'GAGAGATGATCAGTACTCATTA ACTATCCC-3'

These oligonucleotides were engineered to contain *Hind*III and *Bcl*I restriction sites, respectively, which were used to clone the amplified gene in the pSV2 beta globin vector, following standard methods (28). Since *Bcl*I is sensitive to methylation, pSV2 beta globin plasmid was isolated from BZ101 (*dam*⁻) bacterial strain. The relevant structures are depicted in Fig. 1.

Culture and cell lines

Transient expression assays were performed in the simian COS-1 cell line kindly provided by Dr. J. Ortín. Stable clones with the DNA substrate for beta recombinase integrated at different sites of the chromosome were established in the murine cell line NIH/3T3. Both cell lines were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL, Grand Island, NY), supplemented with 10% foetal calf serum (Cultek, Madrid, Spain), 2 mM L-glutamin (Merck, Drmstadt, Germany) and the antibiotics streptomycin (0.1 mg/ml, Sigma, St. Louis, MO) and penicillin (100 U/ml, Sigma).

Transfection conditions and plasmid DNA extraction.

The transient expression experiments were performed in COS-1 cells by transfection with DEAE-dextran, as described (28). Cells were harvested 48 h after transfection and the extrachromosomal DNA was extracted using the method described by Hirt (29). In brief, cell pellets were lysed with SDS (Merck) and treated with proteinase K (Boehringer, Mannheim, Germany) at 37 °C. The genomic DNA was precipitated with 1 M NaCl (Merck). Upon centrifugation, the supernatant was phenol extracted and plasmid DNA precipitated with ethanol and resuspended in water for further experiments.

Stable cell clones with pCB8 DNA randomly inserted at different genome sites were obtained by electroporation in a Bio-Rad Gene Pulser (Hercules, CA) of 2×10^6 NIH/3T3 cells at 220 V, 960 mF, with 20 mg of pCB8 DNA and a marker DNA coding for neomycin resistance at a ratio of 10:1. The neomycin resistant cells were selected with 1 mg/ml G418 (Sigma) for approximately two weeks. The stable clones

obtained were analyzed in Southern experiments (28) or indirect immunofluorescence, as described.

Immunoblotting and immunofluorescence

5 Rabbit polyclonal antibodies against the purified beta recombinase were obtained by conventional techniques (28). beta recombinase was detected by indirect immunofluorescence or by SDS-PAGE followed by immunoblotting.

Transfected cells were grown on coverslips. After 48 h cells were fixed in methanol: acetone (1:1) at -20 °C for 5 min, air dried and rehydrated with PBS. Cells
10 were then incubated with polyclonal anti- beta recombinase antibodies (1:5000 dilution) at room temperature for 30 min, washed three times for 5 min with PBS and incubated again with a fluorescein conjugated anti IgM antibody (DAKO, Glostrup, Denmark) for 1 h at 37 °C in PBS. The cells were mounted in microscope slides and photographed in a fluorescence microscope.

15 For immunoblotting analysis, transiently transfected cells were harvested 48 h after transfection and lysed in RIPA buffer (137 mM NaCl, 20 mM Tris-HCl pH 8, 1 mM MgCl₂, 1 mM CaCl₂, 10 % glycerol, 1 % NP-40, 0.5 % sodium deoxicholate, 0.1 % SDS) (Merck). The lysed fraction was separated through SDS-PAGE, blotted onto nitrocellulose membrane (BIORAD), and incubated with polyclonal anti- beta
20 recombinase antibodies, previously blocked with COS-1 total cell lysate (1/500 dilution). Peroxidase-conjugated anti-IgM antibody (DAKO, Glostrup, Denmark) was used as second antibody. Membranes were processed according to the ECL chemiluminescence detection kit (Amersham, UK).

25 Analysis of recombination products

PCR was performed with the GeneAmp PCR System 2400 from Perkin Elmer (Foster City, CA), equipped with heating cover. Each reaction was carried out with 0.5 mg of genomic DNA or 1/10 of the Hirt preparation according to supplier's instructions. *Taq* polymerase (2.5 U) (Perkin Elmer) was added with Perfect Match
30 PCR Enhancer (Stratagene, La Jolla, CA) after an initial denaturation (10 min, 94°C). Thereafter, the procedure (Touch-Down) was as follows: 80°C 2 min, 5 cycles of denaturation (94°C, 1 min) and annealing/extension at 73°C, 2 min, 5 cycles of 1 min

at 94°C and 2 min at 70°C. This was coupled to 25 cycles of denaturation (94°C, 1 min), annealing (68°C, 30 sec) and extension (72°C, 2 min), and one additional cycle of extension at 72°C for 5 min. For the PCR analysis of the Hirt preparations we used the 16-mer reverse sequencing primer (# 1201) and the 17-mer universal sequencing primer (# 1211) from New England Biolabs (Beverly, MA).

The primers used for the PCR amplification of the Hirt preparations were unsuitable for the analysis of genomic DNA preparations (low T_m). Therefore a new pair of primers was designed:

pBT338UP158, 5'-CCGGCTCGTATGTTGTGTGGAAT-3'

10 pBT338DO802, 5'-TGGCGAAAGGGGGATGTGCTG-3'

Southern analysis of the PCR products was performed by blotting the DNA separated through agarose gels onto nylon membranes (Amersham). Filters were hybridised at 42 °C in 250 mM phosphate buffer (pH 7.2), 50% formamide, 250 mM NaCl, 1 mM EDTA, 7% SDS, and washed in 1X SSC, 0.1% SDS, at room temperature for 30 min, at least twice. The washing temperature was increased when needed. The radioactive labelling of probes was performed with the Prime-It Random Primer Labelling Kit from Stratagene. Nucleotide sequences from the PCR bands of interest were determined by automated fluorescent sequencer and analyzed using Seq-Ed 1.0.3 software (both from Applied Biosystems Inc., Perkin Elmer).

20

RESULTS

Expression of the prokaryotic beta recombinase in mammalian cells.

25 The coding sequence for beta recombinase was cloned in the pSV2 beta globin vector that directs expression from the SV40 virus early promoter. The resulting construction, pSV beta (Figure 1 B), was transiently transfected in COS-1 cells which express SV40 T-antigen. Under these conditions, the expression by plasmids that contain the early SV40 promoter - included in the pSV beta - is amplified. A control plasmid not containing beta recombinase gene, termed pSVc, was also generated.

30

Transiently transfected cells were stained with specific antibodies raised against beta recombinase and viewed in a fluorescence microscope. The pSV beta

transfected cells showed a strong speckled signal located specifically at the cell nucleus, as it can be seen in Figure 2, panels D and E. However, very faint staining was detected in the mock and control transfections (Fig. 2A, B and C). Similar results were obtained when the expression was tested in immunoblot (Fig. 2F). A specific 25 KDa band, corresponding to purified beta protein mobility (c), was developed by the anti- beta recombinase antibodies when COS-1 cells were transfected with the pSV beta plasmid (+) but not in the mock transfected cells (-). These results indicate that beta recombinase can be expressed in eukaryotic environments, showing strong avidity for the nuclear compartment.

10

beta recombinase catalyzes site-specific recombination in transiently transfected mammalian cells.

Unlike Integrases with simple recombination sites, such as Cre and Flp, that require no additional protein factors (4, 5, 7), beta recombinase has a strict requirement for a chromatin-associated protein to mediate DNA recombination (20, 22). beta recombinase binds to the *six* sites and, with the help of a chromatin-associated protein, promotes strand exchange as depicted in Fig. 1A. Mammalian HMG1/HMG2 chromatin-associated protein can substitute, at least *in vitro*, for the function of the analogous *B. Subtilis* or *E. coli* proteins, Hbsu and HU respectively (22).

To determine whether eukaryotic cells could account for this host factor, recombination activity due to beta recombinase was first checked by transient cotransfections in COS-1 cells with plasmids pSV beta (bearing the beta recombinase gene) and pCB8 (the substrate DNA containing two target sites for beta recombinase in direct orientation flanking the *xy/E* gene, see Fig. 1B). Upon recombination, a derivative of pCB8 with a single *six* site should be obtained. The presence of this recombinant product can be easily monitored by PCR amplification of Hirt extracts, using primers complementary to the sequences located upstream of one of the *six* sites (primer a in Fig.1B and Materials & Methods), and downstream of the second *six* site (primer b in Fig.1B and Materials & Methods). In pCB8, these two primers hybridise to sequences located more than 2.7 Kb apart. Under our PCR conditions this fragment

is not efficiently amplified. On the contrary, a 555 bp DNA segment should be amplified from the recombined product. A band of similar length should be obtained when using the same primers and plasmid pBT338 as template, that contains a single *six* site and was used as positive control (Fig.1B). Therefore, after transfection of the COS-1 cells (48h), the extrachromosomal fraction (Hirt extraction) of the cells was purified and the presence of recombination products analyzed by PCR. A clear amplified band of the expected length (555 bp) was observed only when both pCB8 and pSV beta plasmids were cotransfected (see Fig 3); this band was absent when the two DNAs were transfected separately, or when pCB8 was cotransfected with pSVc, the negative control plasmid. The specificity of the amplified band was further confirmed by Southern hybridization (bottom panel) with a probe specific for the *six* site (see Fig 1A). A positive signal of the proper size was detected only in the positive control lane (Fig. 3, pBT338), and in the pCB8/pSV beta cotransfection sample. In lanes corresponding to transfections containing the pSV beta plasmid, the additional band of smaller size detected in the agarose gel was demonstrated to be non-specific, as it did not hybridise to the probe. These results show that beta recombinase is active in an eukaryotic environment, using the machinery/factors provided by the host cell.

beta recombinase promotes recombination in chromatin structures.

It has been described the need of supercoiled DNA as a critical condition for beta recombinase mediated deletions (22). To explore whether beta recombinase can promote DNA rearrangements when two *six* sites form part of the chromatin structure, we established NIH/3T3 cell clones in which the pCB8 construct was integrated at different locations within the mammalian genome. Several stable clones were analyzed by Southern hybridization. Five of them, each one carrying different number of copies (5-75, not shown) of the substrate plasmid, were chosen for transient transfection with the beta recombinase expression plasmid pSV beta. The presence of recombination products was analyzed by PCR of genomic DNA preparations using two primers (pBT338UP158 and pBT338LO802, see Materials and Methods; termed a' and b' respectively in fig. 1B) that should generate a 668 bp amplified fragment. The amplified DNA fragments were detected by Southern blot assays with a probe specific for the *six* site. In all cases, a band that hybridised with the probe (aprox. 660 bp) was

detected in the pSV beta transfected samples (+) (see Fig. 4) . This DNA fragment did not appear when plasmid pSV beta was not included in the transfection (mock transfection, - lanes).

5 The strength of the signal seemed to correlate with the number of copies of the target construction integrated in the chromosome (not shown), suggesting that recombination had occurred at most of the integrated target sequences. This result also suggests that the recombination efficiency is maintained regardless of the position of the target sequences within the chromatin.

10 The fidelity of the recombination mechanism was also confirmed by DNA-sequencing of the amplified bands in the case of clones 1 and 2 (data not shown). The regenerated *six* site (see Fig.1A) obtained after recombination was unaltered. All together, these data show that beta recombinase can accurately and efficiently catalyse site-specific recombination in mammalian genomes. It seems, therefore, that the chromatin structure provides a superhelical torsion suitable for beta recombinase mediated recombination. Although some of the *in vitro* features of beta recombinase activity are not still confirmed in mammalian environments (i.e. inversion, strict intramolecular recombination), we assume that they will be likely maintained in our system. For this reason we define this recombination activity as IRAP for intramolecular recombination activity protein.

20

DISCUSSION

The common genome manipulation techniques, including transgenesis and gene targeting, have opened a new path to understand a wide variety of mechanisms involving diverse genetic functions. However, the usefulness of these systems becomes limited when the expression or inactivation of a given gene has fatal effects on embryo development, (as an example, see ref. 11, 30) or when the lack of gene function can be bypassed or compensated by redundant mechanisms (31-33). Moreover, the effects of gene inactivation outside the tissue of interest are usually unknown and uncontrollable (34).

30

These problems have been partially overcome to some extent with the development and application of the site-specific recombination techniques (reviewed

in 7) that allow spatio-temporal control of the targeting event. This is the case of the Cre-*loxP* and Flp-FRP systems (reviewed in 4 and 3). Nevertheless, although the Cre system has proven to be very useful, it seems to be limited in the sense that it allows only a reduced number of recombination event within the same mouse genome.

5 When a conditional knockout mouse is made using this system, a *loxP* site remains in the genome and constitutes a potential target for another recombination event of unknown consequences. This problem would be overcome if an exclusively intramolecular site-specific recombinase can be used.

In this report we show that the prokaryotic beta recombinase can be
10 functionally expressed in eukaryotic cells and can promote the deletion of DNA sequences located between directly oriented target sites (intramolecular recombination activity mediated by the beta protein) in mammalian cells, IRAP. The protein appears to have high avidity for the nuclear compartment since it was detected after transfection mainly in the nuclear region forming a very condensed and speckled
15 pattern in indirect immunofluorescence. This behaviour is similar to that observed for the Cre enzyme (13). Neither Cre nor beta recombinase present in their primary sequence a canonical or bipartite nuclear localization motif (35, 36). Since they have access to the nuclear compartment, we assume that this localization occurs by diffusion through the nuclear membrane or following the transient disorganization of
20 this membrane during mitosis.

Transient expression of IRAP by plasmid pSV beta was able to promote site-specific recombination between the two directly oriented *six* sites located in the substrate plasmid pCB8 when both plasmids were cotransfected into mammalian cells. As a result, the sequences comprised between the two target sites were deleted from
25 the DNA substrate. The site-specific recombination product was detected by PCR amplification of the Hirt extracts and reassessed by southern hybridization of the amplified products. The presence of this recombination product was strictly dependent on the cotransfection of plasmids pSV beta and pCB8; no recombination products were observed when plasmids pSV beta or pCB8 were transfected separately. It is
30 likely, therefore, that IRAP promotes strand exchange of an extrachromosomal DNA (pCB8 DNA) in the mammalian environment. Since *in vitro* recombination requires a chromatin-associated protein (25), we assume that this factor is provided by the host.

Indeed, it is known that the mammalian HMG1 chromatin associated protein can efficiently stimulate *in vitro* beta -mediated recombination (22, 25). We have recently observed that chromatin-associated proteins from plants can also help beta recombinase to mediated DNA recombination (S. Fernandez, K. Grasser, unpublished), suggesting that IRAP could be suitable for manipulation of plant genomes.

We have also investigated the ability of IRAP to act upon chromatin-integrated target substrates. For this, several stable NIH/3T3 clones were established bearing different numbers of copies (5-75) of the substrate plasmid pCB8 randomly integrated in the host chromatin. Transient IRAP expression led to the excision of the sequences comprised between the two directly oriented *six* sites; the recombination product was detected by PCR amplification from purified genomic DNA and Southern hybridization, and its identity was reassessed by direct DNA sequencing of the amplified product. In these assays, the amount of recombination products seemed to correlate with the copy number of the substrate DNA integrated into the genome, suggesting a high efficiency of recombination and no or low position restriction effects.

The availability of a tool like IRAP system, that can only catalyse intramolecular site-specific recombination, creates a wide variety of possibilities for the programmed modification of eukaryotic genomes, especially if combined with already-existing methods. For instance, a gene of interest could be engineered in order to have an exon or a group of exons flanked with *loxP* /FRT and *six* sites. This would allow the study of gene product influence in two distinct tissues or in the same tissue in different developmental stages, through differential control of Cre/Flp and IRAP expression. Alternatively, two related genes could be inactivated at the same time or at two related stages. The use of inducible promoters would also allow more specific spatio-temporal control of the recombination event.

The IRAP system seems to have potential advantages over the already existing methods. Different authors have reported difficulties for the maintenance of *loxP* sites during the cloning procedures (37), though this seems not to be the case with the *six* sites. As the *six* site is larger than the 34-bp *loxP* site, the existence of potential cryptic sites is less likely, conferring greater target specificity on the recombination reaction.

Such cryptic sites have been described for the Cre recombinase (38). Recently, the beta protein target site sequences necessary and sufficient to yield efficient recombination have been narrowed down to a 90 bp DNA segment that includes two recombinase binding sites (sites I and II); the crossing over point is located at the center of site I (39). It is unlikely that a DNA sequence of this size could be present fortuitously in a genome, therefore minimizing the possibilities of accidental chromosome reorganizations at serendipitous sites. In addition, the enzyme seems to have strong avidity for the nucleus, avoiding the need of introducing sequences for nuclear localization (37).

Preliminary results show that constitutive IRAP expression in NIH/3T3 is compatible with normal cell development (not shown). A transgenic mice model for the *in vivo* expression of the protein is under development. This would demonstrate the *in vivo* effectiveness of the IRAP-*six* system for the modification of precise targets.

As stated above, beta recombinase cannot promote intermolecular recombination *in vitro* or in bacterial cells. Since the potential for generating chromosomal reorganizations would thus be avoided, this tool could be used to promote two or more different specific recombination events at a time in the same animal model regardless of the constitutive expression of IRAP. Thus, the IRAP system offers new possibilities for the development of site-specific genome modifications.

CONCLUSIONS

The development of new strategies for the *in vivo* modification of eukaryotic genomes has become an important objective of current research. Site-specific recombination has proven useful, as it allows controlled manipulation of murine, plant and yeast genomes. Here we describe that the prokaryotic beta recombinase is active in eukaryotic cells. beta recombinase has been functionally expressed in eukaryotic cell lines, demonstrating high avidity for the nuclear compartment and forming a clear speckled pattern when assayed by indirect immunofluorescence. In simian COS-1 cells, transient beta recombinase expression promoted deletion of a DNA fragment laying between two directly oriented specific recognition/crossing over sequences (*six* sites) located as an extrachromosomal DNA substrate. Such intramolecular

recombination activity mediated by the beta protein in mammalian cells was termed IRAP. In stable NIH/3T3 clones bearing different copy numbers of the target sequences integrated at distinct chromosome locations, transient IRAP expression also promoted deletion of the intervening DNA, independent of its position and chromatin structure.

FIGURE LEGENDS

Figure 1. Schematic representation of the site-specific recombination mechanism mediated by IRAP and the plasmids used in this study .

(A) The IRAP (shown as a dimer, open circles) interacts, in the presence of a host factor (HMG-1, shown as a monomer, open polygons) with two identical copies of the *six* site (shaded and open arrows) to form a synaptic complex. This complex is resolved giving rise to a product and a circular intermediate, harboring the intervening sequences, that is finally lost. One full *six* site remains intact in the host cell. (B) The essential features of plasmid pSV β and pCB8 and pBT338 DNA are indicated. The *six* site is shown schematically and sites I and II are highlighted. Orientation of the *six* sites is denoted by the sense of the shaded arrows. The coding region of the *xy/E* gene, initially designed for expression in bacteria, is indicated. The hybridisation sites of the specific primers a/b and a'/b' pairs used for PCR amplification to detect the recombination products and the probe, used for specific hybridisation controls, are indicated.

Figure 2. IRAP expression in mammalian cells detected by indirect immunofluorescence and western blot. COS-1 cells, transfected with the indicated plasmids, were grown on glass coverslips. After 48 h, cells were fixed and stained as indicated. Panels A and B correspond to mock- and pSVc-transfected cells, respectively, incubated first with anti- β recombinase polyclonal antibodies and developed with fluorescein-conjugated anti-rabbit IgG. Panels C, D and E show pSV β -transfected

cells. In panel C, the pSV β -transfected cells were incubated first with preimmune rabbit serum, then developed as above. In panels D and E, showing two different fields of the pSV β -transfected cells, they were incubated with polyclonal anti- β recombinase antibodies and developed as above. Panel F. COS-1 cells, transfected as indicated, were harvested after 48 h and lysed as indicated in Materials & Methods. The whole cell extract proteins were resolved by SDS-PAGE, blotted onto nitrocellulose and analysed by western blot. The figure shows the autoradiography of a western blot incubated first with polyclonal anti- β recombinase antibodies and developed with peroxidase-conjugated anti-IgM. C, purified β recombinase protein (10 ng); -, mock-transfected COS-1 cells; and +, pSV β -transfected COS-1 cells. The molecular mass of the band of interest is indicated.

Figure 3. Functional expression of IRAP assessed in transient transfection experiments. COS-1 cells were transfected with the indicated combinations of plasmids: pCB8, pSV β , pSVc, pSVc + pCB8 and pSV β + pCB8. Hirt extracts were obtained 48 h after transfection. The upper panel shows the result of PCR amplification from the Hirt extracts using the primer a/b pair indicated in Fig. 1B. Mock lane shows the negative controls of the PCR amplification, and lane pBT338 shows the positive control (100 pg of plasmid). The size marker lane corresponds to *Bst*EII-digested lambda DNA (500 ng). The lower panel shows the southern blot analysis of the agarose gel presented in the upper panel using a specific probe for the *six* site (see Fig. 1B). The position of the band of interest is highlighted.

Figure 4. IRAP-mediated site-specific recombination in chromatin-associated targets. Five NIH/3T3 clones (1-5) harboring several copies (approx. 75, 72, 12, 18 and 5, respectively) of pCB8 DNA integrated in different chromosomal locations were isolated and characterized. These clones were transiently transfected, either with (+) or without (-) plasmid pSV β .

Genomic DNA was purified 48 h after transfection and 500 ng of each sample were analyzed by PCR in the conditions described using the primer a'/b' pair (see Fig. 1B). One tenth of each sample was electrophoresed in 0.8% agarose gel, blotted onto nylon membrane and hybridised with an appropriate probe. Controls: (a) pBT338 (100 pg) and (b) pBT338 (100 pg + 500 ng of NIH/3T3 genomic DNA). The size marker corresponds to *Bst*EII-digested lambda DNA (500 ng). The size (0.66 kb) and position of the band of interest is indicated.

REFERENCES

1. Brandon, E. P., Idzerda, R. L. and McKnight, G. S. (1995) *Curr Biol*, **5**, 625-34.
- 15 2. Brandon, E. P., Idzerda, R. L. and McKnight, G. S. (1995) *Curr Biol*, **5**, 758-65.
3. Kilby, N. J., Snaith, M. R. and Murray, J. A. (1993) *Trends Genet*, **9**, 413-21.
4. Sauer, B. (1993) *Methods Enzymol*, **225**, 890-900.
5. Dymecki, S. M. (1996) *Proc Natl Acad Sci U S A*, **93**, 6191-6.
6. Abremski, K. and Hoess, R. (1984) *J Biol Chem*, **259**, 1509-14.
- 20 7. Nash, H. A. (1996) in *Escherichia coli and Salmonella cellular and molecular biology*, ed. F. C. Neidhart, R. I. Curtis, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter and H. E. Umbarger (A. S. M. Press, Wasington D. C.), pp. 2363-76.
8. Sauer, B. and Henderson, N. (1990) *The New Biologist*, **2**, 441-9.
- 25 9. Fukushige, S. and Sauer, B. (1992) *Proc. Natl. Acad. Sci. USA*, **89**, 7905-9.
10. DiSanto, J. P., Muller, W., Guy, G. D., Fischer, A. and Rajewsky, K. (1995) *Proc Natl Acad Sci U S A*, **92**, 377-81.
11. Gu, H., Marth, J. D., Orban, P. C., Mossmann, H. and Rajewsky, K. (1994) *Science*, **265**, 103-6.
- 30 12. Kuhn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995) *Science*, **269**, 1427-9.
13. Orban, P. C., Chui, D. and Marth, J. D. (1992) *Proc. Natl. Acad. Sci. USA*, **89**, 6861-5.

14. Deursen, J. v., Fornerod, M., Rees, B. v. and Grosveld, G. (1995) *Proc. Natl. Acad. Sci. USA*, **92**, 7376-80.
15. Medberry, S. L., Dale, E., Qin, M. and Ow, D. W. (1995) *Nucleic Acids Res*, **23**, 485-90.
- 5 16. Osborne, B. I., Wirtz, U. and Baker, B. (1995) *Plant J*, **7**, 687-701.
17. Pichel, J. G., Lakso, M. and Westphal, H. (1993) *Oncogene*, **8**, 3333-42.
18. Sauer, B. (1996) *Nucleic Acids Res*, **24**, 4608-13.
19. Grindley, N. D. F. (1994) in *Nucleic Acids and Molecular Biology*, ed. F. Eckstein and D. M. J. Lilley (Springer-Verlag, Berlin), pp. 236-67.
- 10 20. Rojo, F. and Alonso, J. C. (1994) *J Mol Biol*, **238**, 159-72.
21. Rojo, F. and Alonso, J. C. (1995) *Nucleic Acids Res*, **23**, 3181-8.
22. Alonso, J. C., Weise, F. and Rojo, F. (1995) *J Biol Chem*, **270**, 2938-45.
23. Ceglowsky, P., Boitsov, A., Chai, S. and Alonso, J. C. (1993) *Gene*, **136**, 1-12.
24. Rojo, F., Weise, F. and Alonso, J. C. (1993) *Febs Lett*, **328**, 169-73.
- 15 25. Alonso, J. C., Gutiérrez, C. and Rojo, F. (1995) *Mol Microbiol*, **18**, 471-8.
26. Miller, A. D. and Rossman, G. J. (1989) *Biotechniques*, **7**, 980-90.
27. Mulligan, R. C., Howard, B. H. and Berg, P. (1979) *Nature*, **277**, 108-14.
28. Maniatis, T., Frisch, E. F. and Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY), pp.
- 20 29. Hirt, B. (1967) *J Mol Biol*, **26**, 365-9.
30. Ioffe, E. and Stanley, P. (1994) *Proc Natl Acad Sci USA*, **91**, 728-32.
31. Schorle, H., Holtschke, T., Hünig, T., Schimpl, A. and Horak, I. (1991) *Nature*, **352**, 621-4.
32. Kühn, R., Rajewsky, K. and Müller, W. (1991) *Science*, **254**, 707-10.
- 25 33. Kopf, M., Lamers, M., Bluethman, M. and Kohler, G. (1994) *Nature*, **376**, 339-45.
34. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whisett, J. A. and Mulligan, R. C. (1994) *Science*, **264**, 713-6.
- 30 35. Nath, S. T. and Nayak, D. P. (1990) *Mol Cel Biol*, **10**, 4139-45.
36. Robbins, J., Dilworth, S. M., Laskey, R. A. and Dingwall, C. (1991) *Cell*, **64**, 615-23.

37. Bergemann, J., Kuhlcke, K., Fehse, B., Ratz, I., Ostertag, W. and Lothar, H. (1995) *Nucleic Acids Res*, **23**, 4451-6.
38. Sauer, B. (1992) *J. Mol. Biol.*, **223**, 911-28.
39. Canosa, I., Rojo, F. and Alonso, J. C. (1996) *Nucleic Acids Res*, **24**, 2712-7.

CLAIMS

- 5 1. Use of prokaryotic beta recombinase and its specific target sequences in eukaryotic cells.
2. Use of prokaryotic beta recombinase for transgenic work in eukaryotic cells.
- 10 3. Use according to claim 1 or 2 for controlling gene expression in eukaryotes.
4. Use according to claim 1 or 2 for manipulating plant genomes in the generation of transgenic plants.
- 15 5. Use according to claim 1 or 2 in which the eukaryotic cells are mammalian cells.
6. Use according to claim 1 or 2 for manipulating pathogenic and Gram positive bacteria.
- 20 7. Use according to any of the previous claim for site-specific intramolecular recombination between two *six* sites in eukaryotic cells.
8. Use according to claim 7 for promotion of two or more different specific recombination events at a time.
- 25 9. Use according to claim 7 for mediating exclusively intramolecular reactions.
10. Use according to claim 7 in which the prokaryotic beta recombinase promotes the deletion of DNA sequences located between directly oriented *six* sites in mammalian
- 30 cells.

11. Use according to claim 7 in which the prokaryotic beta recombinase promotes the inversion of DNA sequences located between inverted repeated *six* sites in mammalian cells.

5 12. Use according to claim 10 in which the prokaryotic beta recombinase promotes deletion of a DNA fragment laying between two directly oriented *six* sites.

13. Use according to claim 12 in which the prokaryotic beta recombinase promotes inversion of a DNA fragment laying between two inversely oriented *six* sites .

10

14. Use according to claim 13 in which the prokaryotic beta recombinase promotes deletion of a DNA fragment laying between direct repeat specific recognition sequences.

15 15. Use according to claim 13 in which the prokaryotic beta recombinase promotes inversion of a DNA fragment laying between inverted repeated specific recognition sequences.

20 16. Use according to claim 10, 11, 12 or 13 in which the specific recognition sequences is located as an extrachromosomal DNA substrate.

17. Use of the gene coding for beta recombinase for catalysing site-specific deletion of DNA sequences when the *six* sites are in a plasmid (extrachromosomal target) introduced in the cell.

25

18. Use of the gene coding for beta recombinase for catalysing site-specific inversion of DNA sequences allocated between the *six* sites that are in a plasmid (extrachromosomal target) introduced in the cell by transfection.

30 19. Use of the gene coding for beta recombinase for catalysing site-specific deletion of DNA sequences when the *six* sequences are integrated in the genome as chromatin associated structures.

20. Use of the gene coding for beta recombinase for catalysing site-specific inversion of DNA sequences when the six sites are integrated in the genome as chromatin associated structures, at several locations.

5

21. Use according to claim 1 to develop new techniques for gene delivery in human gene therapy.

22. Method for development of transgenic animals which includes the use of beta
10 recombinase according to any of claims 1-21.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202

ABSTRACT

The invention relates to the use of prokaryotic recombinase in eukaryotic cells, especially for transgenic work in eukaryotic cells.

It also relates to the use of prokaryotic beta recombinase for intramolecular recombination in eukaryotic cells and for mediating exclusively intramolecular reactions.

The use of the gene coding for beta recombinase for catalysing site-specific resolution (deletion) of DNA sequences when the two target sequences (DNA sequences containing *six* sites) in a plasmid (extrachromosomal target) introduced in the cell by transfection or when the target sequences are integrated in the genome as chromatin associated structures, at several locations is also disclosed.

10
20
30
40
50
60
70
80
90
100





Figure 1

Figure 2






Figure 3




Figure 4